In a report released yesterday, Roanna Ruiz from SVB Securities maintained a Hold rating on Atea Pharmaceuticals (AVIR – Research Report). The company’s shares opened today at $5.04.
Ruiz covers the Healthcare sector, focusing on stocks such as ARS Pharmaceuticals, Lantheus, and Amarin. According to TipRanks, Ruiz has an average return of -4.0% and a 50.63% success rate on recommended stocks.
Atea Pharmaceuticals has an analyst consensus of Hold, with a price target consensus of $8.00.
See today’s best-performing stocks on TipRanks >>
Based on Atea Pharmaceuticals’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $35.47 million. In comparison, last year the company had a GAAP net loss of $42.08 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Atea Pharmaceuticals Inc is a clinical stage biopharmaceutical company engaged in discovering and developing therapies to address the unmet medical needs of patients with severe viral diseases. Its programs are focused on the development of orally- administered direct acting antivirals for the treatment of patients with COVID-19 in the hospital and community settings, the treatment of patients with chronic hepatitis C infection, the treatment of patients with dengue, and the treatment of high-risk patients with severe respiratory syncytial virus infection. The company’s medicinal chemistry, virology, and pharmacology expertise, bolstered by its collective experience in drug development, enables it to pioneer new advancements in antiviral science.
Read More on AVIR:
- Atea Pharmaceuticals Surges Over on Potential Takeover Bid
- Atea Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update
- Atea Pharmaceuticals to Host First Quarter 2023 Financial Results Conference Call on May 8, 2023
- Atea Pharmaceuticals announces U.S. FDA FTD granted to bemnifosbuvir
- Atea Pharmaceuticals Announces U.S. FDA Fast Track Designation Granted to Bemnifosbuvir, an Investigational Oral Antiviral, for the Treatment of COVID-19
